HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsPricing
Theme
Help Login Register
Market News Stocks News ETF News Crypto News

Kymera Therapeutics, Inc.

Contributing Author

Recent Articles by Kymera Therapeutics, Inc.

May-30
Kymera Therapeutics to Announce KT-621 Phase 1 Healthy Volunteer Trial Results on June 2, 2025 KYMR GlobeNewswire
May-29
Kymera Therapeutics to Participate in Upcoming June Investor Conferences KYMR GlobeNewswire
May-19
Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International Conference KYMR GlobeNewswire
May-09
Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases KYMR GlobeNewswire
May-09
Kymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business Update KYMR GlobeNewswire
May-07
Kymera Therapeutics to Participate in Fireside Chat at the BofA Securities 2025 Health Care Conference KYMR GlobeNewswire
Affiliate • Advertise • Theme Settings • Contact • Help • Privacy • Do Not Sell My Data
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.

Upgrade your FINVIZ experience

Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.

Learn more about FINVIZ*Elite